The invention relates to aqueous assemblies.
In an aqueous assembly, a vessel contains a fissile material dissolved in an aqueous solution. Because the fissile material is dissolved in solution, these assemblies tend to have large negative temperature and void coefficients of reactivity caused by the expansion of the solution. Where an aqueous assembly is used in the production of medical isotopes, for example, it is desirable to operate the aqueous assembly at relatively high power levels and, where subcritical, at relatively high neutron multiplication factors. However, the large negative temperature and void coefficients of reactivity can cause undesirable reactivity loss and/or power oscillations, thereby limiting the operating parameters of the aqueous assembly.
In some embodiments, provided is an aqueous assembly having a negative coefficient of reactivity with a magnitude. The aqueous assembly includes a vessel and an aqueous solution, with a fissile solute, supported in the vessel. A reactivity stabilizer is disposed within the aqueous solution to reduce the magnitude of the negative coefficient of reactivity of the aqueous assembly.
In other embodiments, provided are methods of operating an aqueous assembly having a coefficient of reactivity with a magnitude. A vessel is provided. An aqueous solution, including a fissile solute, is added to the vessel. A reactivity stabilizer is added to the aqueous solution, thereby reducing the magnitude of the coefficient of reactivity. A fission reaction is sustained within the aqueous solution.
Other aspects of the invention will become apparent by consideration of the detailed description and accompanying drawings.
Before any embodiments are explained in detail, it is to be understood that the invention is not limited in its application to the details of construction and the arrangement of components set forth in the following description or illustrated in the following drawings. The invention is capable of other embodiments and of being practiced or of being carried out in various ways. Also, it is to be understood that the phraseology and terminology used herein is for the purpose of description and should not be regarded as limiting. The use of “including,” “comprising,” or “having” and variations thereof herein is meant to encompass the items listed thereafter and equivalents thereof as well as additional items. Unless specified or limited otherwise, the terms “mounted,” “connected,” “supported,” and “coupled” and variations thereof are used broadly and encompass direct and indirect mountings, connections, supports, and couplings. Further, “connected” and “coupled” are not restricted to physical or mechanical connections or couplings. It also is specifically understood that any numerical range recited herein includes all values from the lower value to the upper value, e.g., all possible combinations of numerical values between the lowest value and the highest value enumerated are to be considered to be expressly stated in this application. For example, if a concentration range is stated as 1% to 50%, it is intended that values such as 2% to 40%, 10% to 30%, or 1% to 3%, etc., or if a parameter is stated as 0.95-0.99, it is intended that values such as 0.96-0.98, 0.95-0.98, etc. are expressly enumerated in this specification. These are only examples of what is specifically intended.
The devices and methods presented herein may be used with various types and configurations of aqueous assemblies, including, for example, both critical and subcritical aqueous assemblies.
Referring to
The neutron source assembly 14 includes an RF-driven plasma ion source 22. The ion source 22 receives a feed gas, such as a tritium (T) and deuterium (D) mixture. The ion source 22 generates and collimates an ion beam, including D+ and T+ ions, directed along a predetermined pathway 26.
An accelerator 30 receives the D+ and T+ ion beam and accelerates the ion beam to yield an accelerated D+ and T+ ion beam. The accelerator 30 may include a series of acceleration electrodes, or electrostatic plates, for accelerating the D+ and T+ ion beam.
An accelerator target portion 34 of the neutron source assembly 14 receives the accelerated ion beam. The accelerator target portion 34 includes a gas target chamber 38 and, in the illustrated embodiment, a differential pumping system 42. The gas target chamber 38 contains a nuclear particle-deriving target gas that is reactive with the accelerated beam and, in turn, emits nuclear particles, i.e., protons or neutrons. In one construction, the target gas chamber 38 is filled with an approximately equal mix of D and T gas.
Gases that leak from the gas target chamber 38 into the differential pumping section 42 pass through high speed pumps, through a cold trap, and back into the target chamber. The cold traps remove heavier gasses that in time can contaminate the system due to very small leaks.
The accelerated D+ and T+ ion beam striking a mixed target gas of D and T produces D-T and T-D reactions, resulting in the emission of neutrons.
In some constructions of the invention, a neutron multiplier 46 substantially surrounds the gas target chamber. The neutron multiplier 46 may be substantially formed of beryllium or uranium. Multiplication occurs when energetic neutrons from the gas target chamber split beryllium atoms into two helium nuclei and an additional neutron via (n,2n) reactions or when neutrons undergo (n,2n), (n,3n), or (n,f) reactions with uranium. For example, a 14.1 MeV neutron has enough energy to react this way a few times before dropping below the multiplication threshold.
The aqueous target assembly 18 includes a target solution vessel (TSV) 50 and is surrounded by a shield tank 54. The TSV 50 includes an inner wall 58 and an outer wall 62, with an annular target solution volume 66 defined between the inner wall 58 and the outer wall 62. The TSV 50 may be formed, for example, of zircaloy, stainless steel, or aluminum. The TSV 50 substantially surrounds the gas target chamber 38 and, where applicable, the neutron multiplier 46.
The TSV 50 receives an aqueous solution, including a fissile solute, in the annular target solution volume 66. The fissile solute may include U-235 in the form of low enriched uranium (LEU), natural uranium, or other fissionable materials. The uranium may be converted into a salt (e.g., uranyl nitrate, uranyl sulfate, uranyl phosphate, uranyl carbonate, or uranyl fluoride) to increase the solubility, and the pH may be adjusted to further increase solubility. The aqueous solution may include uranium in a concentration of at least about 10 grams-U/liter, at least about 20 grams-U/liter, at least about 30 grams-U/liter, at least about 40 grams-U/liter, at least about 60 grams-U/liter, at least about 80 grams-U/liter, at least about 100 grams-U/liter, at least about 120 grams-U/liter, at least about 140 grams-U/liter, at least about 160 grams-U/liter, at least about 180 grams-U/liter, at least about 200 grams-U/liter, at least about 220 grams-U/liter, at least about 240 grams-U/liter, at least about 260 grams-U/liter, at least about 280 grams-U/liter, or at least about 300 grams-U/liter. The aqueous solution may include uranium in a concentration of less than about 800 grams-U/liter, less than about 750 grams-U/liter, less than about 700 grams-U/liter, less than about 650 grams-U/liter, less than about 600 grams-U/liter, less than about 550 grams-U/liter, less than about 500 grams-U/liter, less than about 450 grams-U/liter, or less than about 400 grams-U/liter. The aqueous solution may include uranium in a concentration of 10 grams-U/liter to about 800 grams-U/liter, about 20 grams-U/liter to about 700 grams-U/liter, about 40 grams-U/liter to about 600 grams-U/liter, about 40 grams-U/liter to about 500 grams-U/liter, or about 50 grams-U/liter to about 400 grams-U/liter. In some embodiments, uranium concentrations in the aqueous solution may be in the range of 10 grams-U/liter to 800 grams-U/liter. In some embodiments, uranium concentrations in the aqueous solution may be in the range of 40 grams-U/liter to 500 grams-U/liter.
In order to substantially maximize the production of medical isotopes with the subcritical hybrid, while substantially ensuring that subcriticality is maintained, an effective neutron multiplication factor (keff) of the system is calculated for a given uranium concentration and enrichment using neutronics computer codes. Neutronics codes that can be used for this analysis included MCNP5, HELIOS, VARIANT, PN2ND, PHOENIX/ANC, KENO, DENOVO, and many others. Desired uranium concentrations and enrichments may then be calculated for a desired keff.
The keff is a measure of a system's proximity to criticality, where:
keff<1.0 is subcritical
keff=1.0 is critical
keff>1.0 is supercritical
In order to substantially maximize the productivity of medical isotopes, while substantially ensuring that subcriticality is maintained, it is desirable to operate the subcritical hybrid 10 with keff of the aqueous target assembly 18 close to 1.0 (e.g., 0.9500-0.9995), because higher keff values increase the efficiency of the system due to increased subcritical multiplication. The hybrid 10 may be operated with keff of at least about 0.7000, at least about 0.7500, at least about 0.8000, at least about 0.8500, at least about 0.9000, or at least about 0.9500. The hybrid 10 may be operated with keff of less than about 0.9995, less than about 0.9990, less than about 0.9980, less than about 0.9970, less than about 0.9960, less than about 0.9950, or less than about 0.9900. The hybrid 10 may be operated with keff of 0.7000 to 0.9995, 0.7500 to 0.9995, 0.8000 to 0.9995, 0.9000 to 0.9995, 0.9500 to 0.9995, or 0.9900 to 0.9995.
A control rod 90 is selectively positionable within the aqueous assembly 74. The control rod 90 includes a material having a high neutron capture cross section. This material may include silver, indium, and cadmium. Other elements that can be used include, for example, boron, cobalt, hafnium, dysprosium, gadolinium, samarium, erbium, and europium, or their alloys and compounds, e.g., high-boron steel, silver-indium-cadmium alloy, boron carbide, zirconium diboride, titanium diboride, hafnium diboride, gadolinium titanate, and dysprosium titanate.
The control rod 90 is positioned within the aqueous assembly 74 by a control rod drive mechanism (CRDM) 94. Inserting the control rod 90 deep within aqueous solution 86 of the reactor vessel 82 reduces the reactivity of the aqueous assembly 74, thereby keeping the aqueous assembly 74 from becoming inadvertently critical (i.e., the control rod maintains keff<1.0). As the control rod 90 is controllably withdrawn from the solution by the CRDM 94, fewer neutrons are captured, and the reactivity within the aqueous assembly 74 increases until keff=1.0 (i.e., the aqueous assembly 74 is critical). Continuing to withdraw the control rod 90 would continue to insert positive reactivity. If the control rod 90 is withdrawn rapidly, and sufficient positive reactivity is inserted into the aqueous assembly 74, the aqueous assembly 74 could become prompt critical: the point where fission can be sustained utilizing prompt neutrons alone. However, this positive rod reactivity may be counteracted by other effects that result in negative reactivity, including warming of the solution and the formation of voids within the solution due to radiolysis, or even boiling.
Since the fissile atoms (e.g., uranium-235) are in solution in an aqueous assembly (e.g., the subcritical aqueous target assembly 18 or the aqueous assembly 74), the mass concentration of uranium decreases as the solution expands with increasing temperature. This expansion displaces uranium from the more neutronically important “high-worth” central region of the TSV 50 (
The thermal expansion effect is compounded by the increase in average neutron energy as the solution's temperature is increased. The increase in thermal neutron temperature decreases the probability of causing fission of uranium-235 relative to the other events that could occur (e.g., escape from the system, capture in low-lying resonances, etc.). This effect may result in a strongly negative temperature coefficient of reactivity. The temperature coefficient of reactivity (αT) is a measure of the change in the reactivity of the system per unit increase in temperature. αT predicts the change in keff for a change in temperature of the aqueous solution. αT of embodiments of the subcritical hybrid 10 or of the aqueous reactor 70 are estimated to be approximately −10 pcm/° F. at 100° F. Values of αT may be calculated with a neutronics computer code. The value of αT may be at least about −100, at least about −90, at least about −80, at least about −70, at least about −60, or at least about −50. The value of αT may be less than about −1, less than about −2, less than about −3, less than about −4, less than about −5, less than about −6, less than about −7, less than about −8, less than about −9, or less than about −10. The value of αT may be −100 to −1, −90 to −2, −80 to −3, −70 to −4, or −60 to −5.
In addition to the negative αT, aqueous assemblies, such as the subcritical aqueous target assembly 18 (
The large negative αT and αvoid can cause two potential issues with aqueous systems: reactivity oscillations and reduced output. Reactivity oscillations can occur as a result of any transients induced on the system (e.g., power change, or pressure change) or due to natural oscillations (e.g., turbulent flow). For example, if the temperature increases, the reactivity feedback mechanisms will cause power to drop, which will lead to a temperature decrease and a subsequent power increase. The cycle will continue until it is externally damped by control systems or until it naturally decays.
The second potential issue is reduced output. For the subcritical aqueous target assembly 18, the output may be reduced because the strong negative temperature and void coefficients result in lower keff values, thereby reducing the subcritical multiplication of the system. The strong negative αT and αvoid may result in a reduction in the operating power level of the system to ensure that there is enough safety margin in the design to account for the power oscillations.
By reducing the magnitude of αT and αvoid, one can reduce the impact of both of these issues.
Certain isotopes have very large capture cross sections for neutrons while also decreasing in density and/or absorbance with a temperature increase, and these isotopes may be called reactivity stabilizers. Reactivity stabilizers absorb neutrons from a nuclear system, preventing the neutrons from causing fission. Some examples of reactivity stabilizers include, but are not limited to, boron-10, gadolinium-155, and gadolinium-157. Boron-10 may be added to the aqueous solution in the form of boric acid (i.e., H3BO3 or B(OH)3). Boric acid may be particularly desirable due to high solubility and low pH. In addition to using soluble boric acid, other physical placements of the boron could be used. Such devices include fixed plates or rods containing boron. Commercial boron-aluminum alloys may be used due to their chemical and radiation stability. Another option would be to place the boron in separate tubes filled with concentrated boric acid.
By adding these reactivity stabilizers to the aqueous solution in the TSV 50 (
A similar response is achieved with αvoid. An increase in solution void displaces the reactivity stabilizer as well as the uranium. Therefore, the reactivity impact of an additional bubble in the solution is reduced due to the competing effects of loss of uranium and loss of reactivity stabilizer.
By adjusting the concentration of the reactivity stabilizers, one can shape the reactivity feedback coefficients αT and αvoid to any desired levels. For example, the reactivity stabilizer concentration may be chosen to lessen the magnitude of αT and αvoid, while still keeping them negative. Negative coefficients help ensure that an increase in system power leads to a decrease in reactivity (self-limiting device); however, coefficients that are too negative lead to the power oscillations described above.
Ultimately, the decreased reactivity coefficients offer increased stability (αT and αvoid) when operating the subcritical hybrid assembly 10, due to the reduced reactivity oscillations. This increased stability also allows for increased production rates of medical isotopes. Because reactivity oscillations are minimized, the subcritical hybrid assembly may be operated with a higher effective neutron multiplication factor (keff).
The subcritical hybrid is provided, including the neutron source assembly, neutron multiplier, and aqueous assembly. An aqueous solution is provided in the TSV. The aqueous solution includes a fissile solute, including LEU.
Desired concentrations of boron, or other reactivity stabilizers, may be calculated using a neutronics computer code. An operator may select desired values of keff, αT, and αvoid, and then calculate a boron concentration. Other input values to the neutronics code include operating conditions of the hybrid assembly, e.g., the geometries of the TSV, shield tank, and neutron multiplier, as well as the volumes, solution chemistry, densities of all materials, source particle energies, nuclear cross section data, and temperatures of all materials.
Once a desired boron concentration is calculated, a boron or boric acid addition is prepared and added to the aqueous solution.
αT and αvoid are calculated for a desired soluble reactivity stabilizer concentration. A first keff value (keff1) is determined to a high degree of accuracy using a base case. Then a small perturbation is made in the variable of interest (e.g., solution temperature), and the new keff value (keff2) is calculated. Optionally, a second perturbation is then made in the opposite direction from the base case, and a third keff value is calculated.
The reactivity coefficient (αT or αvoid) is then calculated from (keff1−keff2)/(keff1*keff2)/ΔZ, where ΔZ is the perturbation in the variable of interest. The two perturbations are used to confirm the calculated reactivity coefficient (αT or αvoid), to determine the slope of the reactivity coefficient, and to provide better statistics through averaging.
Once the subcritical hybrid is operating, αT and αvoid are measured through a combination of instrumentation and calculation. For instance, αT can be inferred by observing the effects of temperature on the power of the system. The temperature of the solution will be measured (at a few specific locations in the solution), and this measured temperature is then mapped to a bulk temperature using fluid dynamics calculations. The power or neutron flux is then measured at that temperature. By knowing the source neutron term, this neutron flux or power can be correlated to a known keff in the system. Then a change in temperature (or change in void) is imposed on the system (such as by altering cooling flow), and the process is repeated. The reactivity coefficient (αT or αvoid) is then calculated using the same formula as above.
The aqueous reactor is provided, including the aqueous assembly. An aqueous solution is provided in the reactor vessel. The aqueous solution includes fissile solute of known concentration and enrichment.
Desired concentrations of boron, or of other reactivity stabilizers, may be calculated using a neutronics computer code. An operator may select desired values of αT, and αvoid, and then calculate a boron concentration. Other input values to the neutronics code may include operating conditions of the aqueous reactor, e.g., the geometries of the reactor vessel and shield tank, as well as the volumes, solution chemistry, densities of all materials, source particle energies, nuclear cross section data, and temperatures of all materials.
Once a desired boron concentration is calculated, a boron or boric acid addition is prepared and added to the aqueous solution.
αT and αvoid are calculated for a desired soluble reactivity stabilizer concentration. The two perturbations are used to confirm the calculated reactivity coefficient (αT or αvoid) to determine the slope of the reactivity coefficient and to provide better statistics through averaging.
Once the aqueous reactor is operating, αT and αvoid are measured through a combination of instrumentation and calculation. For instance, αT can be inferred by observing the effects of temperature on the power of the system. The temperature of the solution will be measured (at a few specific locations in the solution), and this measured temperature is then mapped to a bulk temperature using fluid dynamics calculations. The power or neutron flux is then measured at that temperature. The reactivity coefficient (αT or αvoid) is then calculated using the same formula as above.
Thus, the invention provides, among other things, an aqueous assembly and a control method for the same. Various features and advantages of the invention are set forth in the following claims.
This patent application is a national stage filing under 35 U.S.C. 371 of International Patent Application No. PCT/US2013/031837, filed Mar. 15, 2013, which claims priority to U.S. Provisional Patent Application No. 61/620,735, filed Apr. 5, 2012, the entire contents of all of which are incorporated by reference herein. Priority to these applications is hereby claimed.
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/US2013/031837 | 3/15/2013 | WO | 00 |
Publishing Document | Publishing Date | Country | Kind |
---|---|---|---|
WO2013/187974 | 12/19/2013 | WO | A |
Number | Name | Date | Kind |
---|---|---|---|
2161985 | Szilard | Jun 1939 | A |
2837476 | Busey | Jun 1958 | A |
2853446 | Abbott et al. | Sep 1958 | A |
2907884 | Gale | Oct 1959 | A |
2992333 | Gale | Jul 1961 | A |
3030543 | Luce | Apr 1962 | A |
3079319 | McGrath | Feb 1963 | A |
3085966 | Flora | Apr 1963 | A |
3218235 | Ehler | Nov 1965 | A |
3255092 | Dee, Jr. | Jun 1966 | A |
3258402 | Farnsworth | Jun 1966 | A |
3276965 | Leyse | Oct 1966 | A |
3386883 | Farnsworth | Jun 1968 | A |
3418206 | Hall et al. | Dec 1968 | A |
3448314 | Bounden et al. | Jun 1969 | A |
3473056 | Ferry | Oct 1969 | A |
3530497 | Hirsch et al. | Sep 1970 | A |
3617908 | Greber | Nov 1971 | A |
3624240 | Damm et al. | Nov 1971 | A |
3629588 | Eyrich | Dec 1971 | A |
3634704 | Stix et al. | Jan 1972 | A |
3663858 | Lisitano | May 1972 | A |
3668066 | Hendel et al. | Jun 1972 | A |
3676672 | Meckel et al. | Jul 1972 | A |
3713967 | Hamilton et al. | Jan 1973 | A |
3718836 | Bain et al. | Feb 1973 | A |
3719893 | dePackh | Mar 1973 | A |
3746859 | Hilton et al. | Jul 1973 | A |
3794875 | Stark | Feb 1974 | A |
3799883 | Arino et al. | Mar 1974 | A |
3860482 | Wheelock | Jan 1975 | A |
3925676 | Bigham et al. | Dec 1975 | A |
3992625 | Schmidt et al. | Nov 1976 | A |
4008411 | Brugger et al. | Feb 1977 | A |
4137012 | Porta et al. | Jan 1979 | A |
4147590 | Szekely | Apr 1979 | A |
4202725 | Jarnagin | May 1980 | A |
4311912 | Givens | Jan 1982 | A |
4314879 | Hartman et al. | Feb 1982 | A |
4370295 | Bussard | Jan 1983 | A |
4431580 | Schneider et al. | Feb 1984 | A |
4528003 | Dittrich et al. | Jul 1985 | A |
4529571 | Bacon et al. | Jul 1985 | A |
4650630 | Boyer | Mar 1987 | A |
4663110 | Cheng | May 1987 | A |
4752432 | Bida et al. | Jun 1988 | A |
4793961 | Ehlers et al. | Dec 1988 | A |
4800060 | Goldring | Jan 1989 | A |
4826646 | Bussard | May 1989 | A |
4853173 | Stenbacka | Aug 1989 | A |
4976938 | Knize et al. | Dec 1990 | A |
5037602 | Dabiri et al. | Aug 1991 | A |
5053184 | Cluzeau et al. | Oct 1991 | A |
5126574 | Gallagher | Jun 1992 | A |
5152956 | Bernardet et al. | Oct 1992 | A |
5215703 | Bernardet | Jun 1993 | A |
5280505 | Hughey et al. | Jan 1994 | A |
RE34575 | Klinkowstein et al. | Apr 1994 | E |
5410574 | Masumoto et al. | Apr 1995 | A |
5443732 | Lahoda et al. | Aug 1995 | A |
5468355 | Shefer et al. | Nov 1995 | A |
5482865 | Ferrieri et al. | Jan 1996 | A |
5508010 | Sameh et al. | Apr 1996 | A |
5586153 | Alvord | Dec 1996 | A |
5596611 | Ball | Jan 1997 | A |
5729580 | Millspaugh | Mar 1998 | A |
5745536 | Brainard et al. | Apr 1998 | A |
5745537 | Verschoore | Apr 1998 | A |
5812621 | Takeda et al. | Sep 1998 | A |
5854531 | Young et al. | Dec 1998 | A |
5870447 | Powell et al. | Feb 1999 | A |
5898279 | Ezzedine et al. | Apr 1999 | A |
5910971 | Ponomarev-Stepnoy et al. | Jun 1999 | A |
5920601 | Nigg et al. | Jul 1999 | A |
5940461 | Takeda et al. | Aug 1999 | A |
5977554 | Smith et al. | Nov 1999 | A |
6011825 | Welch et al. | Jan 2000 | A |
6141395 | Nishimura et al. | Oct 2000 | A |
6337055 | Betenekov et al. | Jan 2002 | B1 |
6417634 | Bergstrom | Jul 2002 | B1 |
6544606 | Pennington et al. | Apr 2003 | B1 |
6567492 | Kiselev et al. | May 2003 | B2 |
6593686 | Yui | Jul 2003 | B1 |
6777699 | Miley et al. | Aug 2004 | B1 |
6835358 | Hemingway et al. | Dec 2004 | B2 |
6845137 | Ruth et al. | Jan 2005 | B2 |
6850011 | Monkhorst et al. | Feb 2005 | B2 |
6870894 | Leung et al. | Mar 2005 | B2 |
6891911 | Rostoker et al. | May 2005 | B2 |
6907097 | Leung | Jun 2005 | B2 |
6917044 | Amini | Jun 2005 | B2 |
6922455 | Jurczyk et al. | Jul 2005 | B2 |
6925137 | Forman | Aug 2005 | B1 |
7200198 | Wieland et al. | Apr 2007 | B2 |
7230201 | Miley et al. | Jun 2007 | B1 |
7235216 | Kiselev et al. | Jun 2007 | B2 |
7342988 | Leung et al. | Mar 2008 | B2 |
7362842 | Leung | Apr 2008 | B2 |
7419604 | Atwood | Sep 2008 | B1 |
7968838 | Dent | Jun 2011 | B2 |
7978804 | Groves et al. | Jul 2011 | B2 |
8475747 | Johnson et al. | Jul 2013 | B1 |
8767905 | Neeley | Jul 2014 | B2 |
20020150193 | Leung et al. | Oct 2002 | A1 |
20030152186 | Jurczyk et al. | Aug 2003 | A1 |
20030223528 | Miley et al. | Dec 2003 | A1 |
20040100214 | Erdman | May 2004 | A1 |
20050061994 | Behrouz | Mar 2005 | A1 |
20050069076 | Bricault et al. | Mar 2005 | A1 |
20050082469 | Carlo | Apr 2005 | A1 |
20050129162 | Ruth et al. | Jun 2005 | A1 |
20060023829 | Schenter et al. | Feb 2006 | A1 |
20060062342 | Lepera et al. | Mar 2006 | A1 |
20060104401 | Jongen et al. | May 2006 | A1 |
20060017411 | Hamm | Oct 2006 | A1 |
20070036261 | Kim et al. | Feb 2007 | A1 |
20070108922 | Amaldi | May 2007 | A1 |
20070133734 | Fawcett et al. | Jun 2007 | A1 |
20070160176 | Wada | Jul 2007 | A1 |
20070273308 | Fritzler et al. | Nov 2007 | A1 |
20070297554 | Lavie et al. | Dec 2007 | A1 |
20080023645 | Amelia et al. | Jan 2008 | A1 |
20080224106 | Johnson et al. | Sep 2008 | A1 |
20090129532 | Reyes, Jr. et al. | May 2009 | A1 |
20090213977 | Russell, II et al. | Aug 2009 | A1 |
20090225923 | Neeley et al. | Sep 2009 | A1 |
20090279658 | Leblanc | Nov 2009 | A1 |
20090316850 | Langenbrunner | Dec 2009 | A1 |
20100063344 | Kotschenreuther et al. | Mar 2010 | A1 |
20100193685 | Chu et al. | Aug 2010 | A1 |
20100284502 | Piefer | Nov 2010 | A1 |
20110051876 | Ahfeld et al. | Mar 2011 | A1 |
20110091000 | Stubbers et al. | Apr 2011 | A1 |
20110176648 | Rowland et al. | Jul 2011 | A1 |
20110180698 | Stephenson | Jul 2011 | A1 |
20120300890 | Pfiefer | Nov 2012 | A1 |
20120300891 | Pfiefer | Nov 2012 | A1 |
20190105630 | Hasan | Apr 2019 | A1 |
Number | Date | Country |
---|---|---|
2294063 | Dec 1998 | CA |
1134197 | Oct 1996 | CN |
1922695 | Feb 2007 | CN |
102084434 | Jun 2011 | CN |
535235 | Apr 1993 | EP |
0632680 | Jan 1995 | EP |
1134 771 | Sep 2001 | EP |
1233425 | Aug 2002 | EP |
2711835 | May 1995 | FR |
829093 | Feb 1960 | GB |
869451 | May 1961 | GB |
1187244 | Apr 1970 | GB |
40-24599 | Oct 1965 | JP |
59068143 | Apr 1984 | JP |
03190097 | Aug 1991 | JP |
6160595 | Jun 1994 | JP |
09113693 | May 1997 | JP |
11057043 | Mar 1999 | JP |
2001042098 | Feb 2001 | JP |
3145555 | Mar 2001 | JP |
2001338800 | Dec 2001 | JP |
2002062388 | Feb 2002 | JP |
2002214395 | Jul 2002 | JP |
2005127800 | May 2005 | JP |
2007165250 | Jun 2007 | JP |
2008102078 | May 2008 | JP |
2004115750 | May 2005 | RU |
WO 9114268 | Sep 1991 | WO |
WO 9859347 | Dec 1998 | WO |
WO 0103142 | Jan 2001 | WO |
WO 0131678 | May 2001 | WO |
WO 03019996 | Mar 2003 | WO |
WO 04053892 | Jun 2004 | WO |
WO 06000104 | Jan 2006 | WO |
WO 06015864 | Feb 2006 | WO |
WO 07002455 | Jan 2007 | WO |
WO 07040024 | Apr 2007 | WO |
WO-2007055615 | May 2007 | WO |
WO 09100063 | Aug 2009 | WO |
WO 2009135163 | Nov 2009 | WO |
WO 2009142669 | Nov 2009 | WO |
WO-2009135163 | Nov 2009 | WO |
WO 2013187974 | Dec 2013 | WO |
Entry |
---|
Keele, L. D., and C. R. Schmitt. “Solubility relations of uranyl fluoride-hydrofluoric acid-boric acid.” Journal of Chemical and Engineering Data 17.3 (1972): 330-332. (Year: 1972). |
United States Patent Office Action for U.S. Appl. No. 13/460,033 dated Feb. 1, 2017 (10 pages). |
United States Patent Office Action for U.S. Appl. No. 13/575,826 dated Feb. 21, 2017 (17 pages). |
United States Patent Office Notice of Allowance for U.S. Appl. No. 12/990,758 dated Apr. 10, 2017 (8 pages). |
Canadian Patent Office Action for Application No. 2,723,224 dated Mar. 30, 2017 (4 pages). |
Japanese Patent Office Action for Application No. 2013-249823 dated Oct. 15, 2015 (6 pages) English translation only. |
Canadian Patent Office Action for Application No. 2723224 dated Jun. 5, 2015 (5 pages). |
Chinese Patent Office Action for Application No. 200980123452.6 dated Apr. 22, 2015 (7 pages, English translation included). |
Korean Patent Office Action for Application No. 10-2016-7015856 dated Sep. 27, 2016 (11 pages with English translation). |
Japanese Patent Office Action for Application No. 2013-249823 dated Aug. 16, 2016 (3 pages with English translation). |
Russian Patent Office Action for Application No. 2014144290 dated Oct. 31, 2016 (12 pages with English translation). |
Chinese Patent Office Action for Application No. 201380018865.4 dated Nov. 28, 2016 (17 pages with English translation). |
“The Burr Amendment” “2005 Energy Act,” Congressional Record, pp. S7237-S7244 (Jun. 23, 2005). |
“The Schumer Amendment” “Comprehensive Report on H.R. 776” Congressional Record, p. H12103 (Oct. 5, 1992). |
“U.S. Radioisotope Supply,” American Nuclear Society Position Statement 30:(Jun. 2004). |
Abraham, S., “Remarks by Energy Secretary Spencer Abraham on the Global Threat Reduction Initiative,” Speech to the International Atomic Energy Agency, Vienna, Austria, (May 26, 2004). |
Agostinelli, S., et al., “Geant4—A Simulation Toolkit,” Nuclear Instruments and Methods in Physics Research A, 506:250-303 (2003). |
Angelone, M. et al., “Conceptual Study of a Compact Accelerator-Driven Neutron Source for Radioisotope Production, Boron Neutron Capture Therapy and Fast Neutron Therapy,” Nuc. Instr. & Methods in Physics Res. A:487:585-594 (2002). |
Armstrong, D.D. et al., “Progress Report on Testing of a 100-kV, 125-mA Deuterium Injector,” IEEE Transactions on Nuclear Science NS-26, No. 3 (1979). |
Armstrong, D.D. et al., “Tests of the Intense Neutron Source Prototype” IEEE Transactions on Nuclear Science NS-26, No. 3 (1979). |
Austen, I., “Reactor Shutdown Causing Medical Isotope Shortage,” The New York Times, (Dec. 6, 2007). |
Bakel, A.J. et al., “Thermoxid Sorbents for the Separation and Purification of 99Mo,” 26th International Meeting on RERTR, Vienna, Austria, (Nov. 7-12, 2004). |
Ball, R.M et al., “Present Status of the Use of LEU in Aqueous Reactors to Produce Mo-99,” 1998 International Meeting on Reduced Enrichment for Research and Test Reactors, Sao Paulo,( Oct. 18-23, 1998). |
Barbry, F. “Criticality Accident Studies and Research Performed in the Valduc Criticality Laboratory, France,” IAEA-TECDOC-1601: 39-48 (2008). |
Barnett, C.F., “Atomic Data for Fusion, vol. 1: Collisions of H, H2, He and Li Atoms with Molecules,” ORNL “Redbooks” 6086 (1990). |
Barschall, H.H., “Intense Sources of Fast Neutrons,” Ann. Rev. Nuclear Part. Sci. 28:207-237 (1978). |
Biodex, Pulmonex II® Xenon System: http://www.biodex.com/radio/lungvent/lung_502feat.htm. Accessed: (Jun. 1, 2010). |
Bosch, H., et al. “Improved Formulas for Fusion Cross-Sections and Thermal Reactivities,” Nuclear Fusion 32:4:611-631 (1992). |
Bradley, E. et al., “Homogeneous Aqueous Solution Nuclear Reactors for the Production of Mo-99 and Other Short Lived Radioisotopes,” IAEA-TECDOC-1601: 1-13 (2008). |
Brown, R. W., “The Radiopharmaceutical Industry's Effort to Migrate Toward Mo-99 Production Utilizing LEU,” The 2005 RERTR International Meeting, (Nov. 6-10, 2005). |
Bunker, M.E. “Status Report on the Water Boiler Reactor,” Los Alamos Technical Reports LA-2854 (Oct. 1963). |
Calamai, P., “Chalk River Crisis Sired by AECL,” TheStar.com, (Jan. 19, 2008). |
Cappiello, C. et al., “Lessons Learned from 64 Years of Experience with Aqueous Homogeneous Reactors,” Los Alamos National Laboratory Report LA-UR-10-02947 (May 2010). |
Celona, L. et al., “Status of the TRASCO Intense Proton Source and Emittance Measurements,” Rev. of Sci. Instrum. 75:5: 1423 (2004). |
Chakin, V.P., et al. “High dose neutron irradiation damage in beryllium as blanket material,” Fusion Engineering and Design 58-59: 535-541 (Nov. 2001). |
Chenevert, G.M. et al., “A Tritium Gas Target as an Intense Source of 14 MeV Neutrons,” Nucl. Instr, and Methods 145: 149-155 (1977). |
Cheng, Z. et al., “Preliminary Study of 99Mo Extraction Process from Uranly [sic]-Nitrate Fuel Solution of Medical Isotope Production Reactor,” Homogeneous Aqueous Solution Nuclear reactors for the Production of Mo-99 and Other Short Lived Radioisotopes, IAEA-TECDOC-1601: 27-35 (2008). |
Cipiti, B.B., “Fusion Transmutation of Waste: Design and Analysis of the In-Zinerator Concept,” Sandia Report, SAND2006-6590, (Nov. 2006). |
Cohilis, P., “Recent Advances in the Design of a Cyclotron-Driven, Intense, Subcritical Neutron Source,” Proc. of the Fifth European Particle Physics Conference, EPAC'96, (Jun. 10-14, 1996). |
Committee on Medical Isotope Production Without Highly Enriched Uranium, National Research Council of the National Academies. Medical Isotope Production Without Highly Enriched Uranium. The National Academies Press, Washington, DC (2009). http://www.nap.edu/catalog.php?record_id=12569 Accessed (Jun. 1, 2010). |
Conner, C. et al., “Production of Mo-99 from LEU Targets Acid-side Processing,” 2000 Meeting on Reduced Enrichment for Research and Test Reactors, Las Vegas, Nevada, (Oct. 1-6, 2000). |
DeJesus, O.T. et al., “Preparation and Purification of 77Br-Labeled p-Bromospiroperidol Suitable for in vivo Dopamine Receptor Studies,” J. Label. Comp. Radiopharm., 20: 745-756 (1983). |
Deluca, P.M., “Performance of a Gas Target Neutron Source for Radiotherapy,” Phys. Med. Biol., 23:5: 876-887 (1978). |
Demchenko, P.O., “A Neutron Source on a Basis of a Subcritical Assembly Driven by a Deuteron Linac,” Problems of Atomic Science and Technology, 46:2:31-33 (2006). |
Department of Defense. “Technology Readiness Assessment (TRA) Deskbook,” (May 2005). |
European Patent Office Action for Application No. 09739965.3 dated Sep. 19, 2012 (4 pages). |
Evaluated Nuclear Data File (ENDF): http://www-nds.iaea.org/exfor/endf.htm. Database Version of May 31, 2010. Accessed (May 3, 2010). |
Fraser, S., “Special Examination Report on Atomic Energy of Canada Limited-2007,” OAG Special Examination Report on Atomic Energy of Canada Limited, (Jan. 29, 2008). |
Ganjali, M.R. et al., “Novel Method for the Fast Separation and Purification of Molybdenum(VI) from Fission Products of Uranium with Aminofunctionalized Mesoporous Molecular Sieves (AMMS) Modified by Dicyclohexyl-18-Crown-6 and S-N Tetradentate Schiff's Base,” Analytical Letters, 38:1813-1821 (2005). |
Gobin, R. et al., “High Intensity ECR Ion Source (H+, D+, H− Developments at CEA/Saclay,” Rev. of Sci. Instrum. 73:2: 922 (2002). |
Gohar, Y., “Accelerator-driven Subcritical Facility: Conceptual Design Development,” Nuclear Instruments and Methods in Physics Research A, 562:870-874 (2006). |
Hamilton, T., “Reactor Shutdown Leaves Cancer Patients in Limbo,” TheStar.com, (Dec. 5, 2007). |
Iaea, “Alternative Technologies for 99mTc Generators,” IAEA-TECDOC-852, (Dec. 1995). |
Kahn, L.H., “The Potential Dangers in Medical Isotope Production,” The Bulletin Online, (Mar. 17, 2008). |
King, LDP; Hammond, RP; Leary, JA; Bunker, ME; Wykoff, WR. “Gas Recombination System for a Homogeneous Reactor,” Nucleonics 11:9:25-29 (Sep. 1953). |
Kitten, S. et al., “Solution-reactor-produced Mo-99 using activated carbon to remore[sic] I-131,” Los Alamos National Laboratory Report, LA-UR—98-522 (Jun. 1998). |
Kulcinski, G.L. “Near Term Commercial Opportunities from Long Range Fusion Research,” 12th Annual Meeting on the Technology of Fusion Power, (Jun. 16-20, 1996). |
Kulcinski, G.L., et al., “Alternate Applications of Fusion-Production of Radioisotopes” Fusion Science and Technology 44:559 (2003). |
Kuperman, A.J., “Bomb-Grade Bazaar,” Bulletin of the Atomic Scientists, 62:2:44-50 (Mar./Apr. 2006). |
Kwan, J.D. et al., “A 2.45 GHz High Current Ion Source for Neutron Production,” 17th International Workshop on ECR Ion Sources and Their Applications, Lanzhou, China, (Sep. 17-21, 2006). |
Maclachlan, A. “NRG to Study Potential for Use of LEU for Mo-99,” Nuclear Fuel, 32:26, (Dec. 17, 2007). |
MDS-Nordion. “Mo-99 Fact Sheet: Molybdenum-99 Fission Radiochemical”: http://www.nordion.com/documents/products/Mo-99_Bel.pdf (2009). Accessed (Jun. 1, 2010). |
Meade, C. et al., “Considering the Effects of a Catastrophic Terrorist Attack,” RAND Center for Terrorism Risk Management Policy Report, (2006). |
Mirzadeh, S., “Production Capabilities in U.S. Nuclear Reactors for Medical Radioisotopes,” ORNL report, ORNL/TM-12010, (Nov. 1992). |
Mutalib, A., “Full Scale Demonstration of the Cintichem Process for the Production of Mo-99 Using a Low Enriched Target,” ANL Report ANL/CMT/CP-97560, (Sep. 1999). |
Newsline, “Shortage of Molybdenum-99 Due to Strike at NRU Reactor,” The Journal of Nuclear Medicine, 38:8, (Aug. 1997). |
Nickles, R.J. “Production of a Broad Range of Radionuclides with an 11 MeV Proton Cyclotron,” J Label Comp Radiopharm 30:120 (1991). |
Nortier, F.M. et al., “Investigation of the thermal performance of solid targets for radioisotope production,” Nucl. Instr. and Meth. A 355:236 (1995). |
Ogawa, K; et al., “Development of solution behavior observation system under criticality accident conditions in TRACY,” Journal of Nuclear Science and Technology 37:12:1088-1097 (Dec. 2000). |
Osso, J.A., “Preparation of a Gel of Zirconium Molybdate for use in the Generators of 99Mo-99mTc Prepared with 99Mo Produced by the 98Mo(n,y)99Mo Reaction,” 1998 International Meeting on Reduced Enrichment for Research and Test Reactors, (Oct. 18-23, 1998). |
Piefer, G. “Performance of a Low Pressure, Helicon Driven IEC Helium-3 Fusion Device,” Ph.D. Thesis (Dec. 2006). |
Risler, R., “20 Years of Clinical Therapy Operation with the Fast Neutron Therapy System in Seattle,” Proceedings of the Seventeenth International Conference on Cyclotrons and Their Applications, (Oct. 18-22, 2004). |
Schueller, M.J. et al., “Production and Extraction of 10CO2 From Proton Bombardment of Molten 10B2O3.” Am Inst Physics Press (Oct. 2002). |
Sherman, J. “High-Current Proton and Deuterium Extraction Systems,” Procedings of the 2007 Particle Accelerator Conference, Albuquerque, NM: 1835 (2007). |
Sherman, J.D. et al., “A 75-keV, 140-mA Proton Injector,” Rev. of Scientific Instruments 73:2 917 (Feb. 2002). |
Sherman, J.D. et al., “Proton Injector for cw-Mode Linear Accelerators,” AIP Conf. Proc. 1099: 102 (2008). |
Song, Z. et al., “Minipermanent Magnet High-Current Microwave Ion Source,” Rev. of Sci. Instrum. 77 03A305 (2006). |
Stacey, W.M, “Capabilities of a DT Tokamak Fusion Neutron Source for Driving a Spent Nuclear Fuel Transmutation Reactor,” Nuclear Fusion, 41:2:135-154 (2001). |
Taylor, T. et al., “An Advanced High-Current Low-Emittance dc Microwave Proton Source,” Nucl. Instrum. and Methods in Phys. Res Part A 336:1 (1993). |
Underhill, DW. “The Adsorption of Argon, Krypton and Xenon on Activated Charcoal,” Health Phs. 71:2:160-166 (1996). |
Vandegrift, G. “ANL (GFV) Perspective on Conversion of Mo-99 Production from High- to Low- Enriched Uranium,” Presentation to the National Academies Committee on Medical Isotope Production without Highly Enriched Uranium, Washington D.C. (Apr. 10, 2007). |
Vandegrift, G. F. et al., “RERTR Progress in Mo-99 Production from LEU,” 6th International Topical Meeting Research Reactor Fuel Management (RRFM), Ghent, Belgium, Mar. 17-20 (2002). |
Vandegrift, G.F. et al. “Production of Mo-99 from LEU Targets Base-side Processing,” Meeting on Reduced Enrichment for Research and Test Reactors, Las Vegas, Nevada, (Oct. 1-6, 2000). |
Von Hippel, F.N. et al., “Feasibility of Eliminating the Use of Highly Enriched Uranium in the Production of Medical Radioisotopes,” Science and Global Security, 14:151-162 (2006). |
Vucina, J. L. “Elution Efficiency of Mo-99/Tc-99m Generators,” Facta Universitatis—Series: Physics, Chemistry and Technology, 2:3:125-130 (2001). |
Weidner, J.W. et al. “Production of 13N via Inertial Electrostatic Confinement Fusion,” Fusion Science and Technology 44: 539 (2003). |
William, B. et al., “Proliferation Dangers Associated with Nuclear Medicine: Getting Weapons-Grade Uranium Out Of Radiopharmaceutical Production,” Medicine, Conflict and Survival, 23:4:267-281 (Dec. 2007). |
Zabetakis, M.G., “Flammability Characteristics of Combustible Gases and Vapors,” Bulleltin 627, US Bureau of Mines (1965). |
Ziegler, J. “Stopping and Range of Ions in Matter,” www.srim.org (2008) Accessed (Jun. 1, 2010). |
Bussard, R.W. “Some Physics Considerations of Magnetic Inertial-Electrostatic Confinement: A New Concept for Spherical Converging-flow Fusion,” Fusion Technology 19: 273 (1991). |
Collins, K.E. et al., “Extraction of High Specific Activity Radionuclides from Reactor-Irradiated [alpha]—Phthalocyanine Targets,” Radiochem. Radioanalyt. Lett. 41: 129-132 (1979). |
DeJesus, O.T. et al., “Production and Purification of Zr-89, a Potential PET Antibody Label,” Appl. Radiat. Isotopes., Int.J. Radiat. Appl. Instr. Part A, 41:789-790 (1990). |
Galy, J. et al., “A Neutron Booster for Spallation Sources-Application to Accelerator driven Systems and Isotope Production,” Nuc. Instr. & Methods in Physics Res., 485:3:739-752 (2002). |
Hirsch, R. L. “Inertial-Electrostatic Confinement of Ionized Fusion Gases” J. App. Phys. 38:4522-4534 (1967). |
Kulcinski, G. L., “Non-electric power, near term applications of fusion energy” 18th Symposium on Fusion Engineering, Albuquerque, NM, USA (1999) 5-8. |
Lone, M.A., “Syrup Neutron Cross Sect. 10-40 JV1eV. Rep.:” BNL-NCS-50681, pp. 79-116 (1977). |
Olhoett, G., “Applications and Frustrations in Using Ground Penetrating Radar,” Aerospace and Electronics Systems Magazine, IEEE, 21:2:.12-20, (2002). |
Radel et al., “Detection of Highly Enriched Uranium Using a Pulsed D-D Fusion Source,” Fusion Science and Technology, vol. 52. No. 4, pp. 1087-1091 (2007). |
Russoto, R.L. et al., “Measurement of fuel ion temperatures in ICF implosions using current mode neutron time of flight detectors” Review of Scientific Instrumentation, 61:10:3125-3127 (1990). |
Sabatier, J.M., “A Study on the Passive Detection of Clandestine Tunnels,” 2008 IEEE Conference on Technologies for Homeland Security, pp. 353-358, (May 12-13, 2008). |
Schiller et al., “Electron Beam Technology,” Wiley-Interscience p. 59; Fig. F (XP002545103) (1982). |
Stolarczyk, L.G., “Detection of Underground Tunnels with a Synchronized Electromagnetic Wave Gradiometer,” AFRL-VS-HA-TR-2005-1066, ARFL Technical Report, (2005). |
Yoshikawa, K., et al., “Research and development of landmine detection system by a compact fusion neutron source”, 16th Topical Meeting on Fusion Energy, Madison, WI, USA, O-I-6.4 (2004) 1224-1228. |
Chinese Office Action for Application No. 200980123452.6 dated Feb. 17, 2013 (12 pages—English Translation). |
Chinese Office Action for Application No. 200980123452.6 dated Feb. 11, 2014 (16 pages, English Translation included). |
Japanese Office Action for Application No. 2011/507694 dated Jun. 4, 2013 (Translation and Original, 9 pages). |
PCT/US2011/23024 International Search Report and Written Opinion dated Dec. 6, 2011 (14 pages). |
International Search Report and Written Opinion for Application No. PCT/US2013/031837 dated Dec. 6, 2013 (9 pages). |
PCT/US2008/088485 International Search Report and Written Opinion dated Dec. 18, 2009 (14 pages). |
PCT/US2009/042587 International Preliminary Report on Patentability dated Nov. 11, 2010 (9 pages). |
PCT/US2009/042587 International Search Report and Written Opinion dated Dec. 16, 2009 (9 pages). |
United States Patent Office Action for U.S. Appl. No. 12/990,758 dated May 7, 2014 (14 pages). |
Japanese Office Action for Application No. 2011/507694 dated Jul. 24, 2014 (3 pages). |
Chinese Patent Office Action for Application No. 201510976878.3 dated Nov. 13, 2017 (10 pages). |
United States Patent Office Action for U.S. Appl. No. 13/575,826 dated Nov. 24, 2017 (20 pages). |
United States Patent Office Action for U.S. Appl. No. 13/460,033 dated Nov. 16, 2017 (18 pages). |
Chinese Patent Office Action for Application No. 200980123452.6 dated Oct. 23, 2014 (14 pages, English translation included). |
Chinese Patent Office Action for Application No. 2013800188654 dated Jul. 26, 2017 (16 pages, English translation included). |
Chinese Patent Office Action for Application No. 201510976878.3 dated Mar. 3, 2017 (22 pages, English translation included). |
Japanese Patent Office Action for Application No. 2011-507694 dated Feb. 9, 2015 (3 pages—Statement of relevance included). |
Korean Patent Office Action for Application No. 10-2010-7027045 dated Mar. 30, 2015 (10 pages—English translation included). |
United States Patent Office Action for U.S. Appl. No. 12/990,758 dated Mar. 23, 2015 (17 pages). |
United States Patent Office Action for U.S. Appl. No. 13/460,033 dated Apr. 17, 2015 (13 pages). |
United States Patent Office Action for U.S. Appl. No. 13/575,826 dated Apr. 20, 2015 (13 pages). |
Japanese Patent Office action for Application No. 2013-249823 dated Nov. 10, 2014 (2 pages—Statement of relevance included). |
Tkac, P. et al., “Speciation of molybdenum (IV) in aqueous and organic phases of selected extraction systems,” Separation Science and Technology (2008) 43:2641-2675. |
Canadian Patent Office Action for Application No. 2723224 dated Jun. 10, 2016. |
Korean Patent Office Action for Application No. 10-2010-7027045 dated Feb. 15, 2016. |
Chinese Patent Office Action for Application No. 201380018865.4 dated Feb. 2, 2016. |
European Patent Office Action for Application No. 09739965.3 dated Nov. 26, 2015. |
United States Patent Office Action for U.S. Appl. No. 13/575,826 dated Feb. 5, 2016 (13 pages). |
United States Patent Office Action for U.S. Appl. No. 13/460,033 dated Mar. 7, 2016 (12 pages). |
United States Patent Office Action for U.S. Appl. No. 12/990,758 dated Jul. 21, 2016 (14 pages). |
United States Patent Office Action for U.S. Appl. No. 13/575,826 dated Jul. 27, 2018 (17 pages). |
Chinese Patent Office Action for Application No. 2013800188654 dated Apr. 17, 2018 (7 pages, English translation included). |
United States Patent Office Action for U.S. Appl. No. 13/460,033 dated Jun. 26, 2018 (17 pages). |
Russian Patent Office Decision to Grant a Patent for Invention dated for Application No. 2014144290 dated Jan. 26, 2018 (14 pages). |
Bürck et al., “Sorption Behaviour of Molybdenum on Different Metal Oxide Ion Exchangers,” Solvent Extraction and Ion Exchange 6.1,1988, 167-182. Abstract available online: <https://www.tandfonline.com/doi/abs/10.1080/07366298808917930>. |
Canadian Patent Office Action for Application No. 2,869,559 dated Jan. 25, 2019 (4 pages). |
United States Patent Office Action for U.S. Appl. No. 13/460,033 dated Jan. 10, 2019 (21 pages). |
United States Patent Office Action for U.S. Appl. No. 13/575,826 dated Mar. 15, 2019 (23 pages). |
United States Patent Office Action for U.S. Appl. No. 15/644,497 dated Jul. 16, 2019 (17 pages). |
United States Patent Office Action for U.S. Appl. No. 13/460,033 dated Aug. 15, 2019 (37 pages). |
Korean Patent Office Action for Application No. 10-2014-7031068 dated Aug. 28, 2019 (10 pages, English translation included). |
United States Patent Office Action for U.S. Appl. No. 13/575,826 dated May 18, 2020 (28 pages). |
Canadian Patent Office Action for Application No. 2,869,559 dated Jan. 22, 2020 (4 pages). |
United States Patent Office Action for U.S. Appl. No. 15/644,497 dated Feb. 10, 2020 (16 pages). |
United States Patent Office Notice of Allowance for U.S. Appl. No. 13/460,033 dated Mar. 24, 2020 (8 pages). |
Piefer et al., “Mo-99 Production Using a Subcritical Assembly,”—Mo-99 2011—1st Annual Molybdenum-99 Topical Meeting, Dec. 2011 <https://mo99.ne.anl.gov/2011/pdfs/Mo99%202011%20Web%20Papers/S6-P3_Piefer-Paper.pdf> 7 pages. |
Canadian Patent Office Action for Application No. 2,869,559 dated Nov. 6, 2020 (4 pages). |
United States Patent Office Action for U.S. Appl. No. 15/644,497 dated Sep. 21, 2020 (14 pages). |
United States Patent Office Action for U.S. Appl. No. 15/644,497 dated Apr. 16, 2021 (16 pages). |
United States Patent Office Notice of Allowance for U.S. Appl. No. 13/575,826 dated Dec. 11, 2020 (8 pages). |
Number | Date | Country | |
---|---|---|---|
20150092900 A1 | Apr 2015 | US |
Number | Date | Country | |
---|---|---|---|
61620735 | Apr 2012 | US |